Aquestive Therapeutics, Inc. (NASDAQ: AQST)

Aquestive Therapeutics, Inc. is a pharmaceutical company developing medicines through innovative drug delivery technologies. The company focuses on creating alternative administration methods for complex molecules to replace standard of care therapies. Its primary activities involve its proprietary PharmFilm oral film technology and AdrenaVerse epinephrine prodrug platform alongside manufacturing and supplying licensed commercial products to pharmaceutical partners.

Aquestive Therapeutics, Inc. generates revenue primarily by manufacturing and supplying its licensed commercial products to pharmaceutical partners. Key products include Suboxone for opioid dependence treatment Emylif for ALS Ondif for nausea and vomiting and Sympazan for seizures associated with Lennox Gastaut syndrome. The company also earns revenue from milestone payments and royalties under licensing agreements with licensed product revenue totaling $44.5 million in 2025.

Aquestive Therapeutics, Inc. holds a leading position in oral film drug delivery as the worldwide supplier of the majority of prescription pharmaceutical oral films. In the epinephrine delivery market for allergic reactions it competes with products such as EpiPen marketed by Teva and Auvi Q marketed by Kaleo as well as the recently approved nasal spray neffy from ARS Pharmaceuticals. For epilepsy rescue therapies its Libervant product competes with diazepam rectal gel and nasal spray formulations though it has faced regulatory challenges related to orphan drug exclusivity with Valtoco. Competitive advantages stem from its proprietary drug delivery technologies that offer improved patient convenience reduced gastrointestinal side effects and potential for better therapeutic outcomes compared to traditional administration methods.

Aquestive Therapeutics, Inc. serves pharmaceutical companies through licensing and manufacturing agreements. Specific named customers include Indivior for Suboxone Zambon for Emylif in European markets and Otter Pharmaceuticals a subsidiary of Assertio Holdings for Sympazan. The company has previously maintained licensing agreements with MTPA and Haisco for Exservan in the United States and China. For its proprietary product candidates in development the intended customers are patients and healthcare providers in emergency allergy treatment and epilepsy management.